Search Results - "Senzer, N."

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma by SENZER, Neil N, KAUFMAN, Howard L, GOLDSWEIG, Howard, MARSHALL, Tracey, LOVE, Colin, COFFIN, Robert, NEMUNAITIS, John J, AMATRUDA, Thomas, NEMUNAITIS, Mike, REID, Tony, DANIELS, Gregory, GONZALEZ, Rene, GLASPY, John, WHITMAN, Eric, HARRINGTON, Kevin

“…Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage…”
Get full text

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck by SOULIERES, Denis, SENZER, Neil N, VOKES, Everett E, HIDALGO, Manuel, AGARWALA, Sanjiv S, SIU, Lillian L

“…To determine the efficacy and safety profiles of erlotinib in patients with advanced recurrent and/or metastatic squamous cell cancer of the head and neck…”
Get full text

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer by SEQUIST, Lecia V, GETTINGER, Scott, SWEENEY, Jennifer, WALKER, John R, FRITZ, Christian, ROSS, Robert W, GRAYZEL, David, ENGELMAN, Jeffrey A, BORGER, Darrell R, PAEZ, Guillermo, NATALE, Ronald, SENZER, Neil N, MARTINS, Renato G, JÄNNE, Pasi A, LILENBAUM, Rogerio, GRAY, Jhanelle E, IAFRATE, A. John, KATAYAMA, Ryohei, HAFEEZ, Nafeeza

“…IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in…”
Get full text

MicroRNA profile analysis of human prostate cancers by Tong, A W, Fulgham, P, Jay, C, Chen, P, Khalil, I, Liu, S, Senzer, N, Eklund, A C, Han, J, Nemunaitis, J

“…We examined the microRNA (miRNA) expression profile of 40 prostatectomy specimens from stage T2a/b, early relapse and non-relapse cancer patients, to better…”
Get full text

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis by Santoro, A, Simonelli, M, Rodriguez-Lope, C, Zucali, P, Camacho, L H, Granito, A, Senzer, N, Rimassa, L, Abbadessa, G, Schwartz, B, Lamar, M, Savage, R E, Bruix, J

“…Background: The mesenchymal-epithelial transition factor (MET) receptor is dysregulated in hepatocellular carcinoma (HCC), and tivantinib (ARQ 197) is an oral,…”
Get full text

Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development by Rao, D D, Senzer, N, Cleary, M A, Nemunaitis, J

“…This review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based…”
Get full text

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours by Bowles, D W, Ma, W W, Senzer, N, Brahmer, J R, Adjei, A A, Davies, M, Lazar, A J, Vo, A, Peterson, S, Walker, L, Hausman, D, Rudin, C M, Jimeno, A

“…Background: This phase I, dose-finding study determined the safety, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), pharmacokinetics, and…”
Get full text

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients by Nemunaitis, J, Nemunaitis, M, Senzer, N, Snitz, P, Bedell, C, Kumar, P, Pappen, B, Maples, P B, Shawler, D, Fakhrai, H

“…In a previous dose escalation trial we demonstrated dose related survival correlation to Belagenpumatucel-L. In order to further evaluate safety and response…”
Get full text

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma by Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Jr, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John

“…Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with…”
Get full text

Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer by Eager, R.M, Cunningham, C.C, Senzer, N, Richards, D.A, Raju, R.N, Jones, B, Uprichard, M, Nemunaitis, J

“…Abstract Aims Currently available therapies do improve survival in advanced stage non-small cell lung cancer (NSCLC), but only to a limited degree. Talabostat…”
Get full text

A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients by Nemunaitis, J, Senzer, N, Sarmiento, S, Zhang, Y-A, Arzaga, R, Sands, B, Maples, P, Tong, A W

“…ONYX-015 is an attenuated chimeric human group C adenovirus, which preferentially replicates in and lyses tumor cells that are p53 negative. The purpose of…”
Get full text

Transcription factors: their potential as targets for an individualized therapeutic approach to cancer by Mees, C, Nemunaitis, J, Senzer, N

“…Pro-cancer signals are controlled by the expression and transcription of oncogenes. Transcription of DNA is dependent on the spatially and temporally…”
Get full text

Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial by Epstein, J B, Silverman, Jr, S, Paggiarino, D A, Crockett, S, Schubert, M M, Senzer, N N, Lockhart, P B, Gallagher, M J, Peterson, D E, Leveque, F G

“…Benzydamine was evaluated in patients with head and neck carcinoma for treatment of radiation-induced oral mucositis, a frequent complication of radiation…”
Get full text

Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform by Wu, J, Liu, S, Yu, J, Zhou, G, Rao, D, Jay, C M, Kumar, P, Sanchez, R, Templeton, N, Senzer, N, Maples, P, Nemunaitis, J, Brunicardi, F C

“…RNA interference (RNAi) represents a powerful, new tool for scientific investigation as well as a promising new form of targeted gene therapy, with…”
Get full text

Randomized phase II trial of maintenance autologous tumor cell vaccine (FANG™) following clinical complete response (cCR) in stage III/IV ovarian cancer: Preliminary results by Barve, M, Grosen, E.A, Fine, B.A, Heffernan, T.P, Matthews, C.M, Stringer, C.A, Koon, E.C, Goodman, H.M, Fleming, E.L, DeMars, L.R, Bergman, M.S, Senzer, N, Nemunaitis, J

Get full text

Immune response and survival of refractory cancer patients who received TGF- beta 2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine by Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

“…TAG vaccine is a novel 'triad vaccine' that involves transfection of autologous tumor with a dual plasmid, TGF beta 2 antisense gene and GM-CSF gene. Patients…”
Get full text

Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine by Nemunaitis, J, Senzer, N, Olivares, J, Kumar, P, Barve, M, Kuhn, J, Nemunaitis, T, Magee, M, Yu, Y, Wallraven, G, Pappen, B O, Maples, P B

“…TAG vaccine is a novel ‘triad vaccine’ that involves transfection of autologous tumor with a dual plasmid, TGFβ2 antisense gene and GM-CSF gene. Patients with…”
Get full text

Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference by Rao, D D, Maples, P B, Senzer, N, Kumar, P, Wang, Z, Pappen, B O, Yu, Y, Haddock, C, Jay, C, Phadke, A P, Chen, S, Kuhn, J, Dylewski, D, Scott, S, Monsma, D, Webb, C, Tong, A, Shanahan, D, Nemunaitis, J

“…RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational…”
Get full text

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities by MESSERSMITH, Wells A, LAHERU, Daniel A, SENZER, Neil N, DONEHOWER, Ross C, GROULEFF, Paula, ROGERS, Theresa, KELLEY, Sean K, RAMIES, David A, LUM, Bert L, HIDALGO, Manuel

“…This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor…”
Get full text

Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer by LOESCH, David, GRECO, F. Anthony, PIPPEN, John, LINDQUIST, Deborah, MCINTYRE, Kristi, BLUM, Joanne L, MODIANO, Manuel R, BOEHM, Kristi A, FENG ZHAN, ASMAR, Lina, ROBERT, Nicholas, SENZER, Neil N, BURRIS, Howard A, HAINSWORTH, John D, JONES, Stephen, VUKELJA, Svetislava J, SANDBACH, John, HOLMES, Frankie, SEDLACEK, Scot

“…This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Women (who had performance…”
Get full text